Pheno Therapeutics gains UK MHRA’s CTA for multiple sclerosis therapy trial
Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its …
Post
-
-
How a Fresh Approach to Supply Chains Can Unlock Scaling in Personalized Medicine
Precision medicine represents a new frontier in healthcare. By stratifying patients based on genomic and phenotypic variations, it addresses the …
-
Herd immunity hurdles: The consequences of declining vaccine coverage
In recent years, paediatric immunisation rates in the US have been declining. Vaccines have long been a cornerstone of public …
-
Vistagen reports positive outcomes from Phase IIA cancer cachexia trial
Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the …
-
Alleviant Medical secures $90m to launch pivotal aortic stent trial
Texas medical device firm Alleviant Medical has secured $90m to fund a second pivotal trial of the company’s heart system …
-
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
Moderna lost more than 20% of its value on the stock market as the company delivered slashed revenue guidance for …
-
Clinical research survey results: The key pressures for SMEs and business outlook
The pharma sector is at a crossroads, with major challenges for small and medium-sized businesses driving clinical research. However, there …
-
As avian influenza A(H5N1) concerns continue, mRNA vaccines offer great potential
With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health …
-
Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg …
-
BlueRock accelerates Parkinson’s disease therapy to Phase III
US-based Bayer subsidiary BlueRock Therapeutics has accelerated bemdaneprocel, its investigational cell therapy candidate for Parkinson’s disease, to Phase III trials …
-
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting at …
-
Enhancing patient engagement and outcomes in the NHS
Medication non-adherence is an enduring issue in the UK healthcare system, costing the NHS a staggering £930 million annually.[i] Despite …
-
Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025
Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues …
-
Broader population could benefit from Novartis spinal muscular atrophy treatment
Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA) gene transfer therapy – …
-
Onera’s validation trial of home polysomnography sleep device succeeds
Dutch remote monitoring and sleep aid company, Onera Health’s wireless, patch-based, type-II home-polysomnography system has proven to be as beneficial …
